Connect with us

World News

Omicron stays unhindered by most antibody treatments, show early tests

Published

on

Omicron stays unhindered by most antibody treatments, show early tests

In the context of a global surge in Covid-19 cases, mainly caused by the highly spread Omicron variant, research has shown that antibody treatments that are effective against previous strains of coronavirus may not be effective against new variants.

According to a report in the journal Nature, some preprint publications indicate that Omicron is “fully or partially resistant to all currently available treatments based on these monoclonal antibodies.” Therefore, compared with other variants, many antibody therapy manufacturers have admitted that their products are much less effective on Omicron.

According to the report, the only two antibodies with strong evidence are sotrovimab developed by Vir Biotechnology in San Francisco, California, and GSK, headquartered in London. And DXP-604. US health officials said they will allocate sotrovimab to states based on the severity of Covid-19 and the number of infections and hospitalizations. However, many countries cannot obtain sotrovimab at all. Generally speaking, monoclonal antibody therapy for Covid-19, whether from a single antibody or a mixture of multiple antibodies, can prevent the virus from infecting human cells, thereby reducing the risk of viral infection by up to 85% through the following methods. In the case of Omicron, the researchers quoted in the report that even if the concentration is increased, the therapeutic concentration that should reduce virus replication by half cannot even reach the threshold.

Advertisement

Olivier Schwartz, a virologist at the Pasteur Institute in Paris and co-author of one of the preprints, said: “We did not expect this change in the effectiveness of antibodies.”

Sotrovimab is the best antibody therapy available. However, the study found that the only two antibody therapies that maintain a certain degree of neutralization against Omicron are the therapies developed by AstraZeneca in Cambridge, England.

So far, compared to the highly infectious Delta strain, Omicron has been shown to be more infectious but less severe. Stuart Turville, a virologist at the Kirby Institute in Sydney, Australia, said that although the number of hospitalizations for the new variant has decreased so far, “if Omicron bites hard, it will be a disaster.” He is a co-author of the study. one. Preprint.

Omicron is the main variant of the United States. In the past two weeks, the number of new Covid-19 cases per day has more than tripled, reaching a record average of 480,000 cases. With dozens of infected workers being quarantined, American schools, hospitals and airlines are struggling.

Advertisement

Complete News Source : Hindustan Times

Hollywood

HT Rewind 2024 | Just sequels? How Hollywood stifled creativity as franchises and remakes dominated the box office

Published

on

By

HT Rewind 2024 | Just sequels? How Hollywood stifled creativity as franchises and remakes dominated the box office

With all the highest-grossing films of the year either remakes, spinoffs, or sequels, the franchise model dominated Hollywood in 2024.
A glance at the top ten highest-grossing Hollywood films of 2024 immediately reveals a telling pattern. All ten titles are sequels, remakes, or part of some franchise or cinematic universe. This is, perhaps, the first time in the history of Western cinema when not a single ‘original’ story has managed to be among the year’s biggest films. The failure of much-hyped films like Megalopolis ensured that. But while in some cases, originality failing was a case of bad quality, the sheer overwhelming domination of franchises shows that, at some level, Hollywood has stopped pushing original content. Years from now, when there is an obvious backlash to this trend, 2024 will be seen as the year when it all comes to a head.

Sequels, remakes, and spinoffs galore

Hollywood’s obsession with recognisable IPs is not new. For over three decades, studios have pushed sequels, franchises, and any way to make money based on the audience’s familiarity with characters and worlds. The birth of cinematic universes in 2008 sent that into top gear. This year, the world’s top 10 grossing films include nine Hollywood films – all remakes or sequels -Inside Out 2, Deadpool & Wolverine, Despicable Me 4, Moana 2, Dune Part Two, Wicked, Godzilla x Kong: The New Empire, Kung Fu Panda 4, and Venom: The Last Dance 4. Incidentally, the only non-American film on the list – the Chinese film YOLO – is also a remake, an adaptation of the Japanese film 100 Yen Love.Sequels, remakes, and spinoffs galore

Hollywood’s obsession with recognisable IPs is not new. For over three decades, studios have pushed sequels, franchises, and any way to make money based on the audience’s familiarity with characters and worlds. The birth of cinematic universes in 2008 sent that into top gear. This year, the world’s top 10 grossing films include nine Hollywood films – all remakes or sequels -Inside Out 2, Deadpool & Wolverine, Despicable Me 4, Moana 2, Dune Part Two, Wicked, Godzilla x Kong: The New Empire, Kung Fu Panda 4, and Venom: The Last Dance 4. Incidentally, the only non-American film on the list – the Chinese film YOLO – is also a remake, an adaptation of the Japanese film 100 Yen Love.

Advertisement

Independent cinema falls prey to franchise culture too

For decades, Independent cinema had existed as the bastion of originality and ‘different’ content. Unhindered by the studios’ demands and rules, indie filmmakers experimented with concepts and genres more freely. But this decade has shown that the last bastion is falling, too. The highest-grossing indie film of the year is not just a sequel but a threequel. Terrifer 3, a horror film, made just $2 million, grossed $90 million worldwide, and even beat Joker 2 at the box office. It is now the highest-grossing unrated film in cinema history, and trade insiders feel that may encourage independent cinema to look at repeatable IPs.

Where did the originality go?

Original cinema has existed. Megalopolis, Francis Ford Coppla’s ambitious project, is the biggest example of it. That a filmmaker of his calibre had to invest $120 million of his own money to distribute and release it speaks volumes of the ‘acceptance’ of original ideas in Hollywood. The eventual box office debacle of the film means that studios will be even harder on original ideas that do not check all the boxes for a summer blockbuster.

The road ahead

The clouds do not seem to be dissipating. The first big release of 2025 is Wolf Man, a reboot of a franchise that began eight decades ago. There are spinoffs from the worlds of Star Trek, Bridget Jones, reboots of Snow White, and a fourth Captain America lined up too. And all this is just in the first three months of 2025. Even beyond that, the hope for originality is bleak. Even Christopher Nolan’s next is an adaptation of one of the oldest epics in history – The Odyssey. One can now wait for the next Jordan Peele film or a breakaway sleeper hit to correct the course somewhat. However, given the lack of support from the studios, it remains a tall order.

Group Media Publications
Entertainment News Platforms – anyflix.in      
Construction Infrastructure and Mining News Platform – https://cimreviews.com/
General News Platform – https://ihtlive.com/

Advertisement

Continue Reading
Anyskill-ads

Facebook

Trending